Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-06-21

Clinical Trial Update: (C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating escalating doses of SAN-300 in rheumatoid arthritis completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SAN-300

Snippet

Sponsor: Bausch Health Americas, Inc. | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2021-06-21